| 治疗后嗜酸性粒细胞水平评价预测PD-1单抗治疗胰腺癌患者疗效和预后的价值（附2例） |
| |
| 引用本文： | 卢畅畅,杜 娟,' target='_blank'>,孟凡岩.治疗后嗜酸性粒细胞水平评价预测PD-1单抗治疗胰腺癌患者疗效和预后的价值（附2例）[J].现代肿瘤医学,2023,0(13):2472-2475. |
| |
| 作者姓名： | 卢畅畅 杜 娟 ' target='_blank'> 孟凡岩 |
| |
| 作者单位： | 1.南京中医药大学鼓楼临床医学院肿瘤中心，江苏 南京 210000；2.南京大学医学院附属鼓楼医院肿瘤中心，江苏 南京 210000 |
| |
| 基金项目： | National Natural Science Foundation of China（No.82072926）;国家自然科学基金（编号:82072926）;江苏省自然科学基金（编号:BK20191114）；湖北陈孝平科技发展基金会资助项目（编号:CXPJJH11900001-2019101 ）；江苏省南京市卫生科技发展专项资金资助项目（编号:YKK20080）； |
| |
| 摘 要： | 目的:观察PD-1单抗治疗后长期持续获益的晚期胰腺癌患者外周血嗜酸性粒细胞水平的变化。方法:分析我院2例应用PD-1单抗治疗后长期持续获益的晚期胰腺癌患者的临床资料，探究在治疗过程中嗜酸性粒细胞水平的变化与疗效之间的关系。结果:2例晚期胰腺癌患者采用PD-1单抗治疗后肿瘤病灶均显著缩小，无进展生存期均明显延长，疗效持续时间已分别大于25个月和15个月，治疗期间定期复查发现外周血嗜酸性粒细胞计数及比率较基线均有明显升高，尤其是治疗半年后增高特别显著，且均未出现免疫相关不良反应。结论:嗜酸性粒细胞水平可能是PD-1单抗治疗胰腺癌长期获益的潜在评价指标，治疗过程中嗜酸性粒细胞显著增多提示免疫获益时间长，对于临床疗效评价和预后判断具有一定的预测价值。
|
| 关 键 词： | - |
Evalution of eosinophil level after treatment in predicting the efficacy and prognosis of patients with pancreatic cancer treated with anti-PD-1 antibody therapy(2 cases) |
| |
| LU Changchang,DU Juan,' target='_blank'>,MENG Fanyan.Evalution of eosinophil level after treatment in predicting the efficacy and prognosis of patients with pancreatic cancer treated with anti-PD-1 antibody therapy(2 cases)[J].Journal of Modern Oncology,2023,0(13):2472-2475. |
| |
| Authors: | LU Changchang DU Juan ' target='_blank'> MENG Fanyan |
| |
| Affiliation: | 1.The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine,Jiangsu Nanjing 210000,China;2.The Comprehensive Cancer Center of Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,Jiangsu Nanjing 210000,China. |
| |
| Abstract: | Objective:To compare the eosinophil levels in advanced pancreatic cancer patients who benefited long-term from anti-PD-1 antibody therapy.Methods:To analyze the clinical data of two advanced pancreatic cancer patients who were treated with anti-PD-1 antibody in our hospital,and explore the relationship between eosinophil level and curative effect during treatment.Results:The tumors of the two patients shrunk significantly after immunotherapy with anti-PD-1 antibody and the time of progression free survival were significantly prolonged.The curative effect lasted for more than 25 months and 15 months respectively.During the treatment,it was found that the count and ratio of eosinophils in peripheral blood were significantly increased,especially after half a year of treatment,the increase in eosinophils is particularly significant and there were no immune-related adverse reactions.Conclusion:The level of eosinophils may be a potential evaluation index for the long-term benefit of anti-PD-1 antibody in the treatment of malignant tumors.A significant increase in eosinophils during treatment indicates a long time of immune benefit,and has a certain predictive value for clinical efficacy evaluation and prognosis. |
| |
| Keywords: | eosinophils anti-PD-1 antibody malignant tumor efficacy evaluation |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
